Renalytix Q2 FY2024 revenue $0.7M, net loss $8.5M; CMS sets $950/test

Renalytix plc

2024-Q2 EPS reported -$0.19 revenue$1,168,000

Revenue $0.7M from KidneyIntelX (down from $1.0M YoY); no pharma services revenue.
Net loss improved to $8.5M from $10.4M YoY; cash & equivalents $5.6M at Dec 31, 2023.
CMS finalized $950/test lab fee for kidneyintelX.dkd; NGS resumed claim payment.
Targeting ~33% lower cash burn in Q3 FY2024 vs Q2; annualized burn under $23M.
Published real-world evidence: 61% increase in kidney protective drug prescriptions after testing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Renalytix plc reported second quarter ended December 31, 2023 results: revenue $0.7 million, net income Net loss was $8.5 million.

Period: second quarter ended December 31, 2023
Revenue: $0.7 million
Net income: Net loss was $8.5 million
Result: reported results

Exact text from the filing

During the three months ended December 31, 2023, we recognized $0.7 million of revenue related to sales of KidneyIntelX.

View on SEC.gov

Browse all earnings releases →

Renalytix plc filing history →

Source: SEC EDGAR

accession 0000950170-24-015596

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.